
Adventris Pharmaceuticals
Adventris Pharmaceuticals is a YC Winter 2023 (W23) company. Based in Baltimore, MD, USA. Team of 7.
About Adventris Pharmaceuticals
Summary
Adventris Pharmaceuticals develops off-the-shelf cancer vaccines that target poorly immunogenic oncogenes. Its lead program targets KRAS, the most commonly mutated cancer-driving gene, replacing the need for personalized or patient-specific vaccine manufacturing. The long-term goal is a pan-cancer vaccine administered annually to healthy adults, shifting cancer management from treatment to prevention.
From the Y Combinator listing
Adventris makes cancer vaccines
Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- Baltimore, MD, USA
- 7
- Active
- Early
Founders (3)
- Jen Herbach
- Mark Yarchoan
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works